Gautam Sinha Roy of Motilal Oswal Securities told CNBC-TV18, "Lupin has been one of the favourites from the beginning of the year. May be from a near term perspective we should expect another 7-8 percent kind of upside. In a choppy market, good quality defensive is something that one should always look at and Lupin fits the bill perfectly because not only it is a defensive pharma stock, but also is delivering good results and will continue to be good."
"So, lot of positive tailwinds are there for Lupin. That is the main reason why we continue to like this stock at this point of time," he added.